Clinical-grade, at-home, self-sampling blood collection
Drs. Erwin Berthier and Ben Casavant founded Tasso to help transform the traditional, painful, in-person blood collection process, which has been the standard of care for more than 60 years. Today’s surging demand for telemedicine highlights the shortcomings of a painful test procedure that requires the patient to be present at a healthcare facility. Tasso’s approach focuses on the patient and offers a more convenient and virtually painless process.
The Tasso OnDemand devices enable people to collect their own blood without any training, all from the comfort and privacy of their home. The samples are then mailed to a CLIA-certified, high-complexity clinical laboratory for analysis. These fast and easy-to-use products are being adopted by leading academic medical institutions, government agencies, comprehensive cancer centers, and pharmaceutical organizations around the world for a wide variety of applications, including routine diagnostics, chronic disease monitoring, infectious disease surveillance, athletic and sports testing, virtual clinical trials, global health, and healthcare for under-served populations.
Tasso’s OnDemand devices enable people to collect their own blood without any training, all from the comfort and privacy of their home.
Advantages from using Tasso’s devices include:
- Clinical-grade quality
- Virtually painless process
- Easy-to-use, patient-friendly device
- Self-collection – no training required
- Seamless workflow
– integrated logistics and shipping to CLIA- certified, high-complexity laboratory
Headquartered in Seattle, Washington, Tasso is privately held and funded by grants from the Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, and the National Institutes of Health, by investments from Hambrecht Ducera Growth Ventures, Merck Global Health Innovation Fund, Foresite Capital, Vertical Venture Partners, Techstars, and Cedars Sinai, and by co-development deals with various industry leaders.